Albumin Market Size Worth USD 1.56 Billion in 2032 | Emergen Research

The global albumin market size was USD 0.88 Billion in 2022 and is expected to register a revenue CAGR of 6.0% during the forecast period. The global albumin market is witnessing substantial growth, driven by various factors such as increasing demand for non-therapeutic applications, preference for recombinant albumin, and rising prevalence of rare diseases and life-threatening conditions. A recent market research report highlights key insights into the drivers, restraints, and segment dynamics shaping the albumin market.

Market Drivers:

The albumin market is experiencing a surge in demand due to its vital role in clinical applications. Albumin, the predominant protein in blood plasma, is widely utilized for replenishing depleted fluids and aiding in the recovery of blood volume post medical conditions like trauma, burns, surgeries, infections, and liver diseases. Additionally, it stabilizes drugs and facilitates cellular therapies and regenerative pharmaceuticals.

The market is further propelled by the increasing number of surgical procedures worldwide, especially cancer surgeries, leading to hypoalbuminemia. Moreover, the rising prevalence of rare diseases and life-threatening conditions is boosting the adoption of albumin, particularly for cardiopulmonary bypass surgery and treating hypoalbuminemia in patients with severe injuries and pancreatitis.

Request a Sample Report with Table of Contents and Figures to click Here: @ https://www.emergenresearch.com/request-sample/2806

Market Restraints:

While the market is witnessing significant growth, certain factors restrain its full potential. The increase in prevalence of rare diseases and life-threatening conditions poses a challenge, despite driving albumin usage. Stringent government regulations associated with albumin products adoption also limit market growth.

Segment Insights:

Albumin Product Insights:

• Human Serum Albumin: This segment dominates the market, finding extensive application in various life sciences domains and serving as a critical component in microbial culture media, cellular functions, and drug discovery processes.

• Recombinant Serum Albumin: Expected to witness the fastest growth, driven by its increasing use in R&D activities and addressing life-threatening disorders such as liver diseases, infections, and cardiac surgeries.

Albumin Application Insights:

• Therapeutics Segment: Accounts for the largest market share due to its role in treating burns, trauma cases, cardiac disorders, and drug discovery.

• Drug Formulation & Vaccines Segment: Dominates in terms of market share and is expected to grow rapidly, supported by the increasing number of cancer cases and advancements in albumin-based treatments.

Albumin End-Use Insights:

• Hospitals Segment: Holds the largest market share, driven by the widespread use of albumin in restoring blood volume, managing fluid levels, and supporting various medical procedures and therapies.

Requesting A Customised Report @https://www.emergenresearch.com/request-for-customization/2806

Albumin Top Companies and Competitive Landscape

The global albumin market is fairly fragmented with many large and medium-sized players accounting for the majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective albumin solutions.

• Merck KGaA
• CSL Limited
• Grifols S.A. (Grifols International, S.A.)
• Baxter International Inc.
• China Biologic Products Holdings, Inc.
• Takeda Pharmaceuticals
• Octapharma AG
• Novozymes A/S (Albumedix Ltd.)
• Thermo Fisher Scientific Inc (Affymetrix, Inc.)
• Ventria Bioscience
•
Albumin Latest Industry News

• In April 2020, Apotex Corp. released its generic version of Abraxane, Paclitaxel protein-bound particles for injection (albumin-bound), which was made available in the US. Adenocarcinoma of the pancreas, non-small cell lung cancer, and metastatic breast cancer are all indicated for treatment with paclitaxel protein-bound particles for injectable suspension.

• In May 2020, Bio Products Laboratory (BPL) announced the US launch of ALBUMINEX 5% (human albumin) solution for injection and ALBUMINEX 25% (human albumin) solution for injection. The US and are currently in stock. The US Food and Drug Administration has given the drugs ALBUMINEX 5% and ALBUMINEX 25% approval for the treatment of cardiopulmonary bypass, acute nephrosis, acute respiratory distress syndrome (ARDS), ascites, and hypoalbuminemia, including that resulting from burns.

To Read More About The Report, Visit @https://www.emergenresearch.com/industry-report/albumin-market

Albumin Segment Analysis

For the purpose of this report, Emergen Research has segmented the global albumin market on the basis of product, application, end-use, and region:

• Product Outlook (Revenue, USD Billion; 2019-2032)
o Human serum albumin
o Bovine serum albumin
o Recombinant albumin

• Application Outlook (Revenue, USD Billion; 2019-2032)
o Therapeutics
o Drug formulation & vaccines
o Other applications

• End-Use Outlook (Revenue, USD Billion; 2019-2032)
o Therapeutics
o Drug formulation & vaccines
o Other applications

• Regional Outlook (Revenue, USD Billion; 2019-2032)
o North America
1. U.S.
2. Canada
o Europe
1. Germany
2. France
3. U.K.
4. Italy
5. Spain
6. Benelux
7. Russia
8. Rest of Europe
o Asia Pacific
1. China
2. Japan
3. South Korea
4. India
5. ASEAN Countries
6. Oceania
7. Rest of APAC
o Latin America
1. Brazil
2. Mexico
3. Rest of LATAM
o Middle East & Africa
1. GCC Countries
2. Israel
3. Turkey
4. South Africa
5. Rest of MEA

To Purchase Now, Click Here @https://www.emergenresearch.com/select-license/2806

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

This release was published on openPR.